Blockage of interleukin-1β with canakinumab in patients with Covid-19

There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinumab (300 m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2020-12, Vol.10 (1), p.21775-9, Article 21775
Hauptverfasser:	Landi, Lorenza, Ravaglia, Claudia, Russo, Emanuele, Cataleta, Pierluigi, Fusari, Maurizio, Boschi, Andrea, Giannarelli, Diana, Facondini, Francesca, Valentini, Ilaria, Panzini, Ilaria, Lazzari-Agli, Luigi, Bassi, Paolo, Marchionni, Elisa, Romagnoli, Rossella, De Giovanni, Raffaella, Assirelli, Marina, Baldazzi, Federica, Pieraccini, Fabio, Rametta, Giovanna, Rossi, Lucia, Santini, Luca, Valenti, Ivana, Cappuzzo, Federico
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308 692/699 692/700 Aged Antibodies, Monoclonal, Humanized - administration & dosage C-reactive protein Clinical trials Coronaviruses COVID-19 COVID-19 - mortality COVID-19 Drug Treatment Disease-Free Survival Female Hospitalization Humanities and Social Sciences Humans IL-1β Interleukin-1beta - antagonists & inhibitors Lymphocytes Male Middle Aged Monoclonal antibodies multidisciplinary Oxygen Oxygen - administration & dosage Patients Prospective Studies SARS-CoV-2 Science Science (multidisciplinary) Survival Rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19 pneumonia and treated with canakinumab (300 mg sc). Median time from diagnosis of Covid-19 by viral swab to administration of canakinumab was 7.5 days (range 0–30, IQR 4–11). Median PaO 2 /FiO 2 increased from 160 (range 53–409, IQR 122–210) at baseline to 237 (range 72–533, IQR 158–331) at day 7 after treatment with canakinumab ( p
ISSN:	2045-2322 2045-2322
DOI:	10.1038/s41598-020-78492-y